Kardigan (KARD)
Develops cardiovascular therapies through biologically defined, data-enabled clinical trials.
$21.82
At close+2.22 (+11.33%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions69 holders · as of Jun 30, 2026 | 61.19% | 57.22M shares | |
| Insiders2 holders · as of Aug 13, 2026 | 16.41% | 15.35M shares | |
| Otherremainder | 22.40% | 20.94M shares |
93.50M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Institutions13F, as of Jun 30, 2026
69 holders · 57.22M shares · 69 new positions · 69 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| SCHF (Gpe), LLC | 16.92M | 18.09% | +16.92Mnew | Aug 13, 2026 |
| FMR LLC | 8.91M | 9.53% | +8.91Mnew | Aug 13, 2026 |
| Perceptive Advisors LLC | 8.20M | 8.77% | +8.20Mnew | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 4.21M | 4.50% | +4.21Mnew | Aug 14, 2026 |
| Capital Research Global Investors | 3.60M | 3.85% | +3.60Mnew | Aug 12, 2026 |
| JPMorgan Chase & Co | 1.79M | 1.92% | +1.79Mnew | Aug 12, 2026 |
| AllianceBernstein L.P. | 1.53M | 1.64% | +1.53Mnew | Aug 14, 2026 |
| Liberty Mutual Group Asset Management Inc. | 1.20M | 1.28% | +1.20Mnew | Aug 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Paul Bernsincl. ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC +5 more | 16.20% | 15.10M | 13D | Jun 29, 2026 ↗ |
| HRTG PV, L.P. ("HRTG PV") | 16.00% | 14.87M | 13G | Jun 29, 2026 ↗ |
| Gianakakos Anastasios | 11.10% | 10.47M | 13G | Aug 13, 2026 ↗ |
| Perceptive Advisors LLCincl. Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. +1 more | 8.90% | 8.25M | 13D | Jun 25, 2026 ↗ |
| Edelberg Jay | 5.20% | 4.88M | 13G | Aug 13, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.